Unnatural Products Inc. has entered a multitarget research collaboration with Argenx SE to develop synthetic oral macrocyclic peptide drugs aimed at ‘undruggable’ immune disease targets. The collaboration includes upfront payments and potential milestones totaling approximately $1.5 billion, along with tiered royalties. Their platform employs AI-driven design and high-throughput screening to optimize hit compounds. This alliance exemplifies increasing interest in innovative modalities beyond antibodies within immunology.